For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 59 results
Author Title [ Type(Desc)] Year
Filters: Author is Nathan, Carl F  [Clear All Filters]
Journal Article
Negri A, Javidnia P, Mu R, Zhang X, Vendome J, Gold B, Roberts J, Barman D, Ioerger T, Sacchettini JC et al..  2018.  Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis.. ACS Infect Dis. 4(5):771-787.
Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, Gold B, Ochoada J, Wiernicki T, Masquelin T et al..  2019.  Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.. ACS Infect Dis. 5(2):272-280.
MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan C.  1997.  Identification of nitric oxide synthase as a protective locus against tuberculosis.. Proc Natl Acad Sci U S A. 94(10):5243-8.
Wu K, Koo J, Jiang X, Chen R, Cohen SN, Nathan C.  2012.  Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R.. PLoS One. 7(2):e30512.
Nathan C.  2017.  Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Nathan C, Nussenzweig MC, Pulvirenti T.  2017.  JEM Advisory Editorial Board: Increasing diversity.. J Exp Med.
Nathan CF, Nussenzweig MC, Pulvirenti T.  2019.  JEM Editorial Board: Expanding on the basis of cancer.. J Exp Med. 216(8):1725.
Nathan C.  2013.  A journey in science: promise, purpose, privilege.. Mol Med. 19(1):305-13.
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S.  2008.  A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis.. Nat Med. 14(8):849-54.
Bryk R, Lima CD, Erdjument-Bromage H, Tempst P, Nathan C.  2002.  Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein.. Science. 295(5557):1073-7.
Darby CM, Venugopal A, Ehrt S, Nathan CF.  2011.  Mycobacterium tuberculosis gene Rv2136c is dispensable for acid resistance and virulence in mice.. Tuberculosis (Edinb). 91(5):343-7.
Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, Blackburn C, Gigstad K, Sintchak M, Dick L, Nathan C.  2013.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.. J Am Chem Soc. 135(27):9968-71.
Nathan C.  2006.  Neutrophils and immunity: challenges and opportunities.. Nat Rev Immunol. 6(3):173-82.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J et al..  2016.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 113(31):E4523-30.
Nathan C, Ding A.  2010.  Nonresolving inflammation.. Cell. 140(6):871-82.
Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Quezada LLopez, Somersan S, Warrier T, Little D, Pingle M et al..  2016.  Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.. J Med Chem. 59(13):6027-44.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..  2016.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Bryk R, Griffin P, Nathan C.  2000.  Peroxynitrite reductase activity of bacterial peroxiredoxins.. Nature. 407(6801):211-5.
Nathan C.  2002.  Points of control in inflammation.. Nature. 420(6917):846-52.
K Darwin H, Ehrt S, Gutierrez-Ramos J-C, Weich N, Nathan CF.  2003.  The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.. Science. 302(5652):1963-6.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Lupoli TJ, Fay A, Adura C, Glickman MS, Nathan C.  2016.  Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK.. Proc Natl Acad Sci U S A. 113(49):E7947-E7956.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..  2017.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.